Immune Response Modifications in the Genetic Forms of Parkinson’s Disease: What Do We Know?
Abstract
:1. Introduction
2. LRRK2
3. SNCA
4. Parkin
5. PINK1
6. PARKIN/PINK1 Interaction
7. DJ1
8. GBA
9. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Conflicts of Interest
References
- Poewe, W.; Seppi, K.; Tanner, C.M.; Halliday, G.M.; Brundin, P.; Volkmann, J.; Schrag, A.-E.; Lang, A.E. Parkinson Disease. Nat. Rev. Dis. Primers 2017, 3, 17013. [Google Scholar] [CrossRef] [PubMed]
- Martinez-Martin, P. The Importance of Non-Motor Disturbances to Quality of Life in Parkinson’s Disease. J. Neurol. Sci. 2011, 310, 12–16. [Google Scholar] [CrossRef]
- Cappellano, G.; Carecchio, M.; Fleetwood, T.; Magistrelli, L.; Cantello, R.; Dianzani, U.; Comi, C. Immunity and Inflammation in Neurodegenerative Diseases. Am. J. Neurodegener. Dis. 2013, 2, 89–107. [Google Scholar]
- Harms, A.S.; Thome, A.D.; Yan, Z.; Schonhoff, A.M.; Williams, G.P.; Li, X.; Liu, Y.; Qin, H.; Benveniste, E.N.; Standaert, D.G. Peripheral Monocyte Entry Is Required for Alpha-Synuclein Induced Inflammation and Neurodegeneration in a Model of Parkinson Disease. Exp. Neurol. 2018, 300, 179–187. [Google Scholar] [CrossRef] [PubMed]
- Klann, E.M.; Dissanayake, U.; Gurrala, A.; Farrer, M.; Shukla, A.W.; Ramirez-Zamora, A.; Mai, V.; Vedam-Mai, V. The Gut–Brain Axis and Its Relation to Parkinson’s Disease: A Review. Front. Aging Neurosci. 2022, 13, 782082. [Google Scholar] [CrossRef]
- Kustrimovic, N.; Comi, C.; Magistrelli, L.; Rasini, E.; Legnaro, M.; Bombelli, R.; Aleksic, I.; Blandini, F.; Minafra, B.; Riboldazzi, G.; et al. Parkinson’s Disease Patients Have a Complex Phenotypic and Functional Th1 Bias: Cross-Sectional Studies of CD4+ Th1/Th2/T17 and Treg in Drug-Naïve and Drug-Treated Patients. J. Neuroinflamm. 2018, 15, 205. [Google Scholar] [CrossRef] [PubMed]
- Sulzer, D.; Alcalay, R.N.; Garretti, F.; Cote, L.; Kanter, E.; Agin-Liebes, J.; Liong, C.; McMurtrey, C.; Hildebrand, W.H.; Mao, X.; et al. T Cells from Patients with Parkinson’s Disease Recognize α-Synuclein Peptides. Nature 2017, 546, 656–661. [Google Scholar] [CrossRef] [Green Version]
- De Francesco, E.; Terzaghi, M.; Storelli, E.; Magistrelli, L.; Comi, C.; Legnaro, M.; Mauri, M.; Marino, F.; Versino, M.; Cosentino, M. CD4+ T-Cell Transcription Factors in Idiopathic REM Sleep Behavior Disorder and Parkinson’s Disease. Mov. Disord. 2020. [Google Scholar] [CrossRef]
- Magistrelli, L.; Storelli, E.; Rasini, E.; Contaldi, E.; Comi, C.; Cosentino, M.; Marino, F. Relationship between Circulating CD4+ T Lymphocytes and Cognitive Impairment in Patients with Parkinson’s Disease. Brain Behav. Immun. 2020. [Google Scholar] [CrossRef]
- Contaldi, E.; Magistrelli, L.; Milner, A.V.; Cosentino, M.; Marino, F.; Comi, C. Expression of Transcription Factors in CD4+ T Cells as Potential Biomarkers of Motor Complications in Parkinson’s Disease. J. Parkinsons Dis. 2021, 11, 507–514. [Google Scholar] [CrossRef]
- Riboldi, G.M.; Frattini, E.; Monfrini, E.; Frucht, S.J.; Di Fonzo, A. A Practical Approach to Early-Onset Parkinsonism. J. Parkinsons Dis. 2022, 12, 1–26. [Google Scholar] [CrossRef] [PubMed]
- Polymeropoulos, M.H.; Lavedan, C.; Leroy, E.; Ide, S.E.; Dehejia, A.; Dutra, A.; Pike, B.; Root, H.; Rubenstein, J.; Boyer, R.; et al. Mutation in the Alpha-Synuclein Gene Identified in Families with Parkinson’s Disease. Science 1997, 276, 2045–2047. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- De Oliveira, L.M.; Barbosa, E.R.; Aquino, C.C.; Munhoz, R.P.; Fasano, A.; Cury, R.G. Deep Brain Stimulation in Patients with Mutations in Parkinson’s Disease-Related Genes: A Systematic Review. Mov. Disord. Clin. Pract. 2019, 6, 359–368. [Google Scholar] [CrossRef]
- Sidransky, E.; Nalls, M.A.; Aasly, J.O.; Aharon-Peretz, J.; Annesi, G.; Barbosa, E.R.; Bar-Shira, A.; Berg, D.; Bras, J.; Brice, A.; et al. Multicenter Analysis of Glucocerebrosidase Mutations in Parkinson’s Disease. N. Engl. J. Med. 2009, 361, 1651–1661. [Google Scholar] [CrossRef] [Green Version]
- Ho, D.-H.; Nam, D.; Seo, M.; Park, S.-W.; Seol, W.; Son, I. LRRK2 Inhibition Mitigates the Neuroinflammation Caused by TLR2-Specific α-Synuclein and Alleviates Neuroinflammation-Derived Dopaminergic Neuronal Loss. Cells 2022, 11, 861. [Google Scholar] [CrossRef] [PubMed]
- Kubo, M.; Kamiya, Y.; Nagashima, R.; Maekawa, T.; Eshima, K.; Azuma, S.; Ohta, E.; Obata, F. LRRK2 Is Expressed in B-2 but Not in B-1 B Cells, and Downregulated by Cellular Activation. J. Neuroimmunol. 2010, 229, 123–128. [Google Scholar] [CrossRef] [PubMed]
- Deng, I.; Corrigan, F.; Zhai, G.; Zhou, X.-F.; Bobrovskaya, L. Lipopolysaccharide Animal Models of Parkinson’s Disease: Recent Progress and Relevance to Clinical Disease. Brain Behav. Immun.-Health 2020, 4, 100060. [Google Scholar] [CrossRef] [PubMed]
- Park, J.; Lee, J.-W.; Cooper, S.C.; Broxmeyer, H.E.; Cannon, J.R.; Kim, C.H. Parkinson Disease-Associated LRRK2 G2019S Transgene Disrupts Marrow Myelopoiesis and Peripheral Th17 Response. J. Leukoc. Biol. 2017, 102, 1093–1102. [Google Scholar] [CrossRef] [Green Version]
- Chen, Z.; Laurence, A.; O’Shea, J.J. Signal Transduction Pathways and Transcriptional Regulation in the Control of Th17 Differentiation. Semin. Immunol. 2007, 19, 400–408. [Google Scholar] [CrossRef] [Green Version]
- Gardet, A.; Benita, Y.; Li, C.; Sands, B.E.; Ballester, I.; Stevens, C.; Korzenik, J.R.; Rioux, J.D.; Daly, M.J.; Xavier, R.J.; et al. LRRK2 Is Involved in the IFN-γ Response and Host Response to Pathogens. J. Immunol. 2010, 185, 5577–5585. [Google Scholar] [CrossRef] [Green Version]
- Cook, D.A.; Kannarkat, G.T.; Cintron, A.F.; Butkovich, L.M.; Fraser, K.B.; Chang, J.; Grigoryan, N.; Factor, S.A.; West, A.B.; Boss, J.M.; et al. LRRK2 Levels in Immune Cells Are Increased in Parkinson’s Disease. NPJ Parkinson’s Dis. 2017, 3, 11. [Google Scholar] [CrossRef]
- Bliederhaeuser, C.; Zondler, L.; Grozdanov, V.; Ruf, W.P.; Brenner, D.; Melrose, H.L.; Bauer, P.; Ludolph, A.C.; Gillardon, F.; Kassubek, J.; et al. LRRK2 Contributes to Monocyte Dysregulation in Parkinson’s Disease. Acta Neuropathol. Commun. 2016, 4, 123. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Kuss, M.; Adamopoulou, E.; Kahle, P.J. Interferon-γ Induces Leucine-Rich Repeat Kinase LRRK2 via Extracellular Signal-Regulated Kinase ERK5 in Macrophages. J. Neurochem. 2014, 129, 980–987. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Yan, J.; Zhao, W.; Gao, C.; Liu, X.; Zhao, X.; Wei, T.; Gao, A.Z. Leucine-rich Repeat Kinase 2 Regulates Mouse Dendritic Cell Migration by ORAI2. FASEB J. 2019, 33, 9775–9784. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Gillardon, F.; Schmid, R.; Draheim, H. Parkinson’s Disease-Linked Leucine-Rich Repeat Kinase 2(R1441G) Mutation Increases Proinflammatory Cytokine Release from Activated Primary Microglial Cells and Resultant Neurotoxicity. Neuroscience 2012, 208, 41–48. [Google Scholar] [CrossRef]
- Panagiotakopoulou, V.; Ivanyuk, D.; De Cicco, S.; Haq, W.; Arsić, A.; Yu, C.; Messelodi, D.; Oldrati, M.; Schöndorf, D.C.; Perez, M.-J.; et al. Interferon-γ Signaling Synergizes with LRRK2 in Neurons and Microglia Derived from Human Induced Pluripotent Stem Cells. Nat. Commun. 2020, 11, 5163. [Google Scholar] [CrossRef]
- Marrone, L.; Bus, C.; Schöndorf, D.; Fitzgerald, J.C.; Kübler, M.; Schmid, B.; Reinhardt, P.; Reinhardt, L.; Deleidi, M.; Levin, T.; et al. Generation of IPSCs Carrying a Common LRRK2 Risk Allele for in Vitro Modeling of Idiopathic Parkinson’s Disease. PLoS ONE 2018, 13, e0192497. [Google Scholar] [CrossRef] [Green Version]
- Magistrelli, L.; Contaldi, E.; Comi, C. The Impact of SNCA Variations and Its Product Alpha-Synuclein on Non-Motor Features of Parkinson’s Disease. Life 2021, 11, 804. [Google Scholar] [CrossRef]
- Shameli, A.; Xiao, W.; Zheng, Y.; Shyu, S.; Sumodi, J.; Meyerson, H.J.; Harding, C.V.; Maitta, R.W. A Critical Role for Alpha-Synuclein in Development and Function of T Lymphocytes. Immunobiology 2016, 221, 333–340. [Google Scholar] [CrossRef] [Green Version]
- Alvarez-Erviti, L.; Couch, Y.; Richardson, J.; Cooper, J.M.; Wood, M.J.A. Alpha-Synuclein Release by Neurons Activates the Inflammatory Response in a Microglial Cell Line. Neurosci. Res. 2011, 69, 337–342. [Google Scholar] [CrossRef]
- Gao, H.-M.; Zhang, F.; Zhou, H.; Kam, W.; Wilson, B.; Hong, J.-S. Neuroinflammation and α-Synuclein Dysfunction Potentiate Each Other, Driving Chronic Progression of Neurodegeneration in a Mouse Model of Parkinson’s Disease. Environ. Health Perspect. 2011, 119, 807–814. [Google Scholar] [CrossRef] [Green Version]
- La Vitola, P.; Balducci, C.; Baroni, M.; Artioli, L.; Santamaria, G.; Castiglioni, M.; Cerovic, M.; Colombo, L.; Caldinelli, L.; Pollegioni, L.; et al. Peripheral Inflammation Exacerbates A-synuclein Toxicity and Neuropathology in Parkinson’s Models. Neuropathol. Appl. Neurobiol. 2021, 47, 43–60. [Google Scholar] [CrossRef]
- Roodveldt, C.; Labrador-Garrido, A.; Gonzalez-Rey, E.; Fernandez-Montesinos, R.; Caro, M.; Lachaud, C.C.; Waudby, C.A.; Delgado, M.; Dobson, C.M.; Pozo, D. Glial Innate Immunity Generated by Non-Aggregated Alpha-Synuclein in Mouse: Differences between Wild-Type and Parkinson’s Disease-Linked Mutants. PLoS ONE 2010, 5, e13481. [Google Scholar] [CrossRef] [Green Version]
- Haenseler, W.; Zambon, F.; Lee, H.; Vowles, J.; Rinaldi, F.; Duggal, G.; Houlden, H.; Gwinn, K.; Wray, S.; Luk, K.C.; et al. Excess α-Synuclein Compromises Phagocytosis in IPSC-Derived Macrophages. Sci. Rep. 2017, 7, 9003. [Google Scholar] [CrossRef] [PubMed]
- Lücking, C.B.; Dürr, A.; Bonifati, V.; Vaughan, J.; De Michele, G.; Gasser, T.; Harhangi, B.S.; Meco, G.; Denèfle, P.; Wood, N.W.; et al. Association between Early-Onset Parkinson’s Disease and Mutations in the Parkin Gene. N. Engl. J. Med. 2000, 342, 1560–1567. [Google Scholar] [CrossRef] [PubMed]
- Alves da Costa, C.; Duplan, E.; Rouland, L.; Checler, F. The Transcription Factor Function of Parkin: Breaking the Dogma. Front. Neurosci. 2019, 12, 965. [Google Scholar] [CrossRef]
- Frank-Cannon, T.C.; Tran, T.; Ruhn, K.A.; Martinez, T.N.; Hong, J.; Marvin, M.; Hartley, M.; Trevino, I.; O’Brien, D.E.; Casey, B.; et al. Parkin Deficiency Increases Vulnerability to Inflammation-Related Nigral Degeneration. J. Neurosci. 2008, 28, 10825–10834. [Google Scholar] [CrossRef]
- Singh, K.; Han, K.; Tilve, S.; Wu, K.; Geller, H.M.; Sack, M.N. Parkin Targets NOD2 to Regulate Astrocyte Endoplasmic Reticulum Stress and Inflammation. Glia 2018, 66, 2427–2437. [Google Scholar] [CrossRef]
- Cherian, A.; Divya, K.P. Genetics of Parkinson’s Disease. Acta Neurol. Belg. 2020, 120, 1297–1305. [Google Scholar] [CrossRef] [PubMed]
- Matheoud, D.; Sugiura, A.; Bellemare-Pelletier, A.; Laplante, A.; Rondeau, C.; Chemali, M.; Fazel, A.; Bergeron, J.J.; Trudeau, L.-E.; Burelle, Y.; et al. Parkinson’s Disease-Related Proteins PINK1 and Parkin Repress Mitochondrial Antigen Presentation. Cell 2016, 166, 314–327. [Google Scholar] [CrossRef] [Green Version]
- Matheoud, D.; Cannon, T.; Voisin, A.; Penttinen, A.-M.; Ramet, L.; Fahmy, A.M.; Ducrot, C.; Laplante, A.; Bourque, M.-J.; Zhu, L.; et al. Intestinal Infection Triggers Parkinson’s Disease-like Symptoms in Pink1−/− Mice. Nature 2019, 571, 565–569. [Google Scholar] [CrossRef] [PubMed]
- Narendra, D.; Walker, J.E.; Youle, R. Mitochondrial Quality Control Mediated by PINK1 and Parkin: Links to Parkinsonism. Cold Spring Harb. Perspect. Biol. 2012, 4, a011338. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Quinn, P.M.J.; Moreira, P.I.; Ambrósio, A.F.; Alves, C.H. PINK1/PARKIN Signalling in Neurodegeneration and Neuroinflammation. Acta Neuropathol. Commun. 2020, 8, 189. [Google Scholar] [CrossRef]
- Borsche, M.; König, I.R.; Delcambre, S.; Petrucci, S.; Balck, A.; Brüggemann, N.; Zimprich, A.; Wasner, K.; Pereira, S.L.; Avenali, M.; et al. Mitochondrial Damage-Associated Inflammation Highlights Biomarkers in PRKN/PINK1 Parkinsonism. Brain 2020, 143, 3041–3051. [Google Scholar] [CrossRef] [PubMed]
- Sliter, D.A.; Martinez, J.; Hao, L.; Chen, X.; Sun, N.; Fischer, T.D.; Burman, J.L.; Li, Y.; Zhang, Z.; Narendra, D.P.; et al. Parkin and PINK1 Mitigate STING-Induced Inflammation. Nature 2018, 561, 258–262. [Google Scholar] [CrossRef] [PubMed]
- Pankratz, N.; Pauciulo, M.W.; Elsaesser, V.E.; Marek, D.K.; Halter, C.A.; Wojcieszek, J.; Rudolph, A.; Shults, C.W.; Foroud, T.; Nichols, W.C. Mutations in DJ-1 Are Rare in Familial Parkinson Disease. Neurosci. Lett. 2006, 408, 209–213. [Google Scholar] [CrossRef] [Green Version]
- Trudler, D.; Weinreb, O.; Mandel, S.A.; Youdim, M.B.H.; Frenkel, D. DJ-1 Deficiency Triggers Microglia Sensitivity to Dopamine toward a pro-Inflammatory Phenotype That Is Attenuated by Rasagiline. J. Neurochem. 2014, 129, 434–447. [Google Scholar] [CrossRef]
- Bandopadhyay, R. The Expression of DJ-1 (PARK7) in Normal Human CNS and Idiopathic Parkinson’s Disease. Brain 2004, 127, 420–430. [Google Scholar] [CrossRef] [Green Version]
- Waak, J.; Weber, S.S.; Waldenmaier, A.; Görner, K.; Alunni-Fabbroni, M.; Schell, H.; Vogt-Weisenhorn, D.; Pham, T.; Reumers, V.; Baekelandt, V.; et al. Regulation of Astrocyte Inflammatory Responses by the Parkinson’s Disease-associated Gene DJ–1. FASEB J. 2009, 23, 2478–2489. [Google Scholar] [CrossRef] [Green Version]
- Zhang, L.; Wang, J.; Wang, J.; Yang, B.; He, Q.; Weng, Q. Role of DJ-1 in Immune and Inflammatory Diseases. Front. Immunol. 2020, 11, 994. [Google Scholar] [CrossRef]
- Zhou, Y.; Shi, X.; Chen, H.; Zhang, S.; Salker, M.S.; Mack, A.F.; Föller, M.; Mak, T.W.; Singh, Y.; Lang, F. DJ-1/Park7 Sensitive Na+/H+ Exchanger 1 (NHE1) in CD4+ T Cells: DJ-1 Sensitive NHE1 in T Cells. J. Cell Physiol. 2017, 232, 3050–3059. [Google Scholar] [CrossRef] [PubMed]
- Singh, Y.; Trautwein, C.; Dhariwal, A.; Salker, M.S.; Alauddin, M.; Zizmare, L.; Pelzl, L.; Feger, M.; Admard, J.; Casadei, N.; et al. DJ-1 (Park7) Affects the Gut Microbiome, Metabolites and the Development of Innate Lymphoid Cells (ILCs). Sci. Rep. 2020, 10, 16131. [Google Scholar] [CrossRef] [PubMed]
- Moy, L.Y.; Zeevalk, G.D.; Sonsalla, P.K. Role for Dopamine in Malonate-Induced Damage In Vivo in Striatum and In Vitro in Mesencephalic Cultures. J. Neurochem. 2002, 74, 1656–1665. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Singh, Y.; Chen, H.; Zhou, Y.; Föller, M.; Mak, T.W.; Salker, M.S.; Lang, F. Differential Effect of DJ-1/PARK7 on Development of Natural and Induced Regulatory T Cells. Sci. Rep. 2016, 5, 17723. [Google Scholar] [CrossRef] [PubMed]
- Cilia, R.; Tunesi, S.; Marotta, G.; Cereda, E.; Siri, C.; Tesei, S.; Zecchinelli, A.L.; Canesi, M.; Mariani, C.B.; Meucci, N.; et al. Survival and Dementia in GBA -associated Parkinson’s Disease: The Mutation Matters. Ann. Neurol. 2016, 80, 662–673. [Google Scholar] [CrossRef]
- Huh, Y.E.; Chiang, M.S.R.; Locascio, J.J.; Liao, Z.; Liu, G.; Choudhury, K.; Kuras, Y.I.; Tuncali, I.; Videnovic, A.; Hunt, A.L.; et al. β-Glucocerebrosidase Activity in GBA -Linked Parkinson Disease: The Type of Mutation Matters. Neurology 2020, 95, e685–e696. [Google Scholar] [CrossRef]
- Chahine, L.M.; Qiang, J.; Ashbridge, E.; Minger, J.; Yearout, D.; Horn, S.; Colcher, A.; Hurtig, H.I.; Lee, V.M.-Y.; Van Deerlin, V.M.; et al. Clinical and Biochemical Differences in Patients Having Parkinson Disease with vs without GBA Mutations. JAMA Neurol. 2013, 70, 852. [Google Scholar] [CrossRef] [Green Version]
- Kobo, H.; Bar-Shira, A.; Dahary, D.; Gan-Or, Z.; Mirelman, A.; Goldstein, O.; Giladi, N.; Orr-Urtreger, A. Down-Regulation of B Cell-Related Genes in Peripheral Blood Leukocytes of Parkinson’s Disease Patients with and without GBA Mutations. Mol. Genet. Metab. 2016, 117, 179–185. [Google Scholar] [CrossRef]
- Alcalay, R.N.; Levy, O.A.; Waters, C.H.; Fahn, S.; Ford, B.; Kuo, S.-H.; Mazzoni, P.; Pauciulo, M.W.; Nichols, W.C.; Gan-Or, Z.; et al. Glucocerebrosidase Activity in Parkinson’s Disease with and without GBA Mutations. Brain 2015, 138, 2648–2658. [Google Scholar] [CrossRef] [Green Version]
- Kim, H.-J.; Jeon, B.; Song, J.; Lee, W.-W.; Park, H.; Shin, C.-W. Leukocyte Glucocerebrosidase and β-Hexosaminidase Activity in Sporadic and Genetic Parkinson Disease. Parkinsonism Relat. Disord. 2016, 23, 99–101. [Google Scholar] [CrossRef]
- Atashrazm, F.; Hammond, D.; Perera, G.; Dobson-Stone, C.; Mueller, N.; Pickford, R.; Kim, W.S.; Kwok, J.B.; Lewis, S.J.G.; Halliday, G.M.; et al. Reduced Glucocerebrosidase Activity in Monocytes from Patients with Parkinson’s Disease. Sci. Rep. 2018, 8, 15446. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Usenko, T.; Bezrukova, A.; Basharova, K.; Panteleeva, A.; Nikolaev, M.; Kopytova, A.; Miliukhina, I.; Emelyanov, A.; Zakharova, E.; Pchelina, S. Comparative Transcriptome Analysis in Monocyte-Derived Macrophages of Asymptomatic GBA Mutation Carriers and Patients with GBA-Associated Parkinson’s Disease. Genes 2021, 12, 1545. [Google Scholar] [CrossRef] [PubMed]
- Grozdanov, V.; Bliederhaeuser, C.; Ruf, W.P.; Roth, V.; Fundel-Clemens, K.; Zondler, L.; Brenner, D.; Martin-Villalba, A.; Hengerer, B.; Kassubek, J.; et al. Inflammatory Dysregulation of Blood Monocytes in Parkinson’s Disease Patients. Acta Neuropathol. 2014, 128, 651–663. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Nissen, S.K.; Shrivastava, K.; Schulte, C.; Otzen, D.E.; Goldeck, D.; Berg, D.; Møller, H.J.; Maetzler, W.; Romero-Ramos, M. Alterations in Blood Monocyte Functions in Parkinson’s Disease. Mov. Disord. 2019, 34, 1711–1721. [Google Scholar] [CrossRef]
- Barak, V.; Acker, M.; Nisman, B.; Kalickman, I.; Abrahamov, A.; Zimran, A.; Yatziv, S. Cytokines in Gaucher’s Disease. Eur. Cytokine Netw. 1999, 10, 205–210. [Google Scholar]
- Galper, J.; Balwani, M.; Fahn, S.; Waters, C.; Krohn, L.; Gan-Or, Z.; Dzamko, N.; Alcalay, R.N. Cytokines and Gaucher Biomarkers in Glucocerebrosidase Carriers with and without Parkinson Disease. Mov. Disord. 2021, 36, 1451–1455. [Google Scholar] [CrossRef]
- Thaler, A.; Omer, N.; Giladi, N.; Gurevich, T.; Bar-Shira, A.; Gana-Weisz, M.; Goldstein, O.; Kestenbaum, M.; Shirvan, J.C.; Cedarbaum, J.M.; et al. Mutations in GBA and LRRK2 Are Not Associated with Increased Inflammatory Markers. J. Parkinsons Dis. 2021, 11, 1285–1296. [Google Scholar] [CrossRef]
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Magistrelli, L.; Contaldi, E.; Vignaroli, F.; Gallo, S.; Colombatto, F.; Cantello, R.; Comi, C. Immune Response Modifications in the Genetic Forms of Parkinson’s Disease: What Do We Know? Int. J. Mol. Sci. 2022, 23, 3476. https://doi.org/10.3390/ijms23073476
Magistrelli L, Contaldi E, Vignaroli F, Gallo S, Colombatto F, Cantello R, Comi C. Immune Response Modifications in the Genetic Forms of Parkinson’s Disease: What Do We Know? International Journal of Molecular Sciences. 2022; 23(7):3476. https://doi.org/10.3390/ijms23073476
Chicago/Turabian StyleMagistrelli, Luca, Elena Contaldi, Francesca Vignaroli, Silvia Gallo, Federico Colombatto, Roberto Cantello, and Cristoforo Comi. 2022. "Immune Response Modifications in the Genetic Forms of Parkinson’s Disease: What Do We Know?" International Journal of Molecular Sciences 23, no. 7: 3476. https://doi.org/10.3390/ijms23073476